The global eubiotics market was valued at USD 4.82 billion in 2020 and is projected to grow at a CAGR of 7.8% during the forecast period. Factors driving the growth of the eubiotics market include growing cognizance about feed quality and safety, ban on the use of antibiotics as growth promoters and high demand for safe human food.
The global eubiotics market is segmented based on type, livestock, function and form. Type is further split into probiotics, prebiotics, organic acids, and essential oils. The probiotics segment dominated the market in 2019. On the basis of livestock, the market is segmented into swine, poultry, ruminants, aquatic animals, and others. The poultry segment was the largest market in 2019. By function, the market is segmented into nutrition & gut health, yield, immunity, and productivity. The nutrition & gut health segment accounted for the largest share. By form, the market is segmented into dry and liquid. The dry form dominated the market in 2019 and is expected to retain its position by 2028.
Regionally, Europe accounted for the largest market share of the global eubiotics market attributable to biotechnological innovations for eubiotic products. Leading players of the global eubiotics market include Cargill, E. I. du Pont de Nemours and Company, BASF SE, Koninklijke DSM N. V., Novozymes, Chr. Hansen A/S, Calpis Co., Ltd., Kemin Industries, Inc., Lesaffre Group, Lallemand Inc., among others.
Key segments of the global eubiotics market
Type Overview, 2018-2028 (USD Billion)
- Organic acids
- Essential oils
Livestock Overview, 2018-2028 (USD Billion)
- Aquatic animals
- Other livestock
Function Overview, 2018-2028 (USD Billion)
- Nutrition and gut health
Form Overview, 2018-2028 (USD Billion)
Regional Overview, 2018-2028 (USD Billion)
- North America
- United Kingdom
- Asia Pacific
- Latin America
- Middle East & Africa
- South Afric
Reasons for the study
- Increasing global demand for quality animal products
- Ban on the use of antibiotics as growth promoters
- Increasing consumer awareness with respect to preventive health care and nutrition
What does the report include?
- The study on the global eubiotics market includes qualitative factors such as drivers, restraints and opportunities
- The study covers qualitative and quantitative analysis of the market segmented on the basis of type, livestock, function and form. Moreover, the study provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the above-mentioned segments
- The study includes the profiles of key players in the market with a significant global and/or regional presence
Who should buy this report?
- The report on the global eubiotics market is suitable for all the players across the value chain including product manufacturing companies, suppliers/distributors, R&D labs, CROs, healthcare organizations, medical reimbursement and insurance providers
- Venture capitalists and investors looking for more information on the future outlook of the global eubiotics market
Consultants, analysts, researchers, and academicians looking for insights shaping the global eubiotics market
The key issue which precipitated the ban was the growing problem of antimicrobial resistance in human medicine. While it is generally accepted that the greater majority of the resistance originates from medical use to treat human disease, concerns were expressed that the use of antimicrobials in animals may be a contributory factor to human resistance. The tightening restrictions on the use of AGPs, the mounting consumer pressure on food safety and the changing consumer preference are the key drivers to the search for viable alternatives to in-feed antibiotics. Several well researched eubiotics have shown promising results in university and field trials and have eventually been successfully used in commercial conditions. Organic acids like benzoic acid, essential oil compounds, probiotics and nucleotides can be used either as single products or one can combine two or more eubiotics to achieve a higher response. While there has been a number of research studies on the effect of eubiotics, more need to be conducted to fully understand how they act and how farmers can get the most out of their use to maintain gut health and reduce the need for antibiotic treatment.
On the basis of livestock, the eubiotics market is segmented into swine, poultry, ruminants, aquatic animals, and others, which include horses, sheep, and birds. Despite being beset with a host of diseases, global pig production continues to grow, especially in Asia. However, with the spiraling feed raw material prices, farmers are constantly finding ways to maximize the genetic potential of pigs and one of these measures is to maintain a healthy gut. While in the past, farmers relied heavily on AGPs in modulating the intestinal ecosystem, the banning of AGPs in Europe has intensified the search for alternatives to antibiotics.
For the affluent consumers in the West, particularly in Europe, animal welfare, quality, safety and sustainability are important considerations. Retailers on the other hand are keeping close tabs on these developments and for them traceability and certifications are a must to stay in business. In the USA, the evolution is less marked than in Europe although organic production is increasing as consumers in large US cities are demanding more natural products. The high profile food scandals and diseases have driven the public to look for safety which they trust the FDA/USDA to ensure. Two major companies have started marketing ‘antibiotic-free meat’. All these consumer demands come with a price tag; hence both in the USA and Europe the retail price is still a key decision parameter especially during crisis times.